Syndax Pharmaceuticals Inc Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Syndax Pharmaceuticals Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2015 to Q3 2024.
  • Syndax Pharmaceuticals Inc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$84.1M, a 64.5% decline year-over-year.
  • Syndax Pharmaceuticals Inc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$297M, a 68.7% decline year-over-year.
  • Syndax Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2023 was -$209M, a 40.2% decline from 2022.
  • Syndax Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$149M, a 699% decline from 2021.
  • Syndax Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2021 was $24.9M.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$297M -$84.1M -$33M -64.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 -$264M -$68.1M -$23.4M -52.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-05
Q1 2024 -$241M -$72.4M -$31.3M -76% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-05
Q4 2023 -$209M -$72.5M -$33.3M -84.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 -$176M -$51.1M -$15.7M -44.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 -$160M -$44.6M -$7.04M -18.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-05
Q1 2023 -$153M -$41.1M -$3.96M -10.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-05
Q4 2022 -$149M -$39.2M -$135M -141% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 -$13.9M -$35.4M -$14.8M -71.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $818K -$37.6M -$14.7M -64% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-02
Q1 2022 $15.5M -$37.2M -$9.45M -34.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-02
Q4 2021 $24.9M $96.2M +$117M Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 -$91.7M -$20.6M -$202K -0.99% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$91.5M -$22.9M -$5.85M -34.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-03
Q1 2021 -$85.6M -$27.7M -$12.5M -82% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-03
Q4 2020 -$73.2M -$20.4M -$6.42M -45.9% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-12
Q3 2020 -$66.7M -$20.4M -$7.61M -59.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$59.1M -$17.1M -$2.15M -14.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-15
Q1 2020 -$57M -$15.2M -$934K -6.53% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-15
Q4 2019 -$56M -$14M +$4.84M +25.7% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-12
Q3 2019 -$60.9M -$12.8M +$4.51M +26% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-12
Q2 2019 -$65.4M -$14.9M +$3.47M +18.9% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-12
Q1 2019 -$68.9M -$14.3M +$5.1M +26.3% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-12
Q4 2018 -$74M -$18.8M +$267K +1.4% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-05
Q3 2018 -$74.2M -$17.3M -$2.25M -14.9% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-05
Q2 2018 -$72M -$18.4M -$4.75M -34.8% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-05
Q1 2018 -$67.2M -$19.4M -$6.43M -49.5% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-05
Q4 2017 -$60.8M -$19.1M -$8.29M -76.6% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-07
Q3 2017 -$52.5M -$15.1M -$119K -0.8% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-07
Q2 2017 -$52.4M -$13.6M -$5.28M -63.2% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-07
Q1 2017 -$47.1M -$13M -$2.64M -25.6% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-07
Q4 2016 -$44.5M -$10.8M -$5.55M -105% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-08
Q3 2016 -$38.9M -$15M -$7.24M -93.6% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-08
Q2 2016 -$31.7M -$8.36M -$2.14M -34.5% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-08
Q1 2016 -$29.5M -$10.3M -$5.42M -110% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-08
Q4 2015 -$24.1M -$5.26M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-14
Q3 2015 -$7.73M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-14
Q2 2015 -$6.21M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-14
Q1 2015 -$4.91M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.